One study concluded that SGLT2 inhibitors are associated with a decreased risk of HF hospitalization and mortality in HF patients compared to placebo, regardless of diabetes status, the specific SGLT2 inhibitors used, or the length of follow-up. This evidence concerns the gene SLC5A2 and hydrops fetalis.